| t01 |
drug(s), clinical, diseases, development, therapeutic, review, studies, current, trials |
127 |
10 |
| t02 |
antiviral, viral, viruses, virus, host, replication, antiviral_drugs, development, viral_infections, infections |
145 |
7 |
| t03 |
in_vitro, vitro, infection, vivo, effect, in_vivo, activity, cells, chloroquine, results |
76 |
16 |
| t04 |
screening, discovery, drug, virtual, compounds, docking, lead, virtual_screening, silico, in_silico |
40 |
2 |
| t05 |
coronavirus, sars-cov-2, COVID-19, sars-cov, SARS, syndrome, mers-cov, respiratory, coronaviruses, middle |
52 |
38 |
| t06 |
peptide(s), antimicrobial, natural, amps, natural_products, products, bacteria, activities, antibiotics |
44 |
0 |
| t07 |
delivery, rnai, sirna(s), interference, antisense, gene, nucleic, drug_delivery, RNA |
36 |
0 |
| t08 |
influenza, M2, IAV, H5N1, H1N1, pandemic, neuraminidase, avian, oseltamivir, seasonal |
26 |
1 |
| t09 |
inhibitor(s), norovirus, protease(s), molecule, enzyme, 3clpro, small_molecule, x-ray |
22 |
3 |
| t10 |
ebola, EBOV, GS-5734, ebola_virus, EVD, fatality, niv, africa, favipiravir, fever |
22 |
1 |
| t11 |
hepatitis, DNA, simplex, HCV, HRV, cytomegalovirus, HCMV, infections, herpes, HBV |
24 |
0 |
| t12 |
agonists, diabetes, derivatives, ferroquine, antimalarial(s), malaria, effects, niclosamide, HCT |
24 |
0 |
| t13 |
JEV, RSV, diarrhea, encephalitis, assay, VEEV, SCV, aureus, rotavirus, fda-approved |
19 |
1 |
| t14 |
UPS, ubiquitin, IFN, oncolytic, proteasome, dubs, signaling, CEP, oncolytic_viruses, cancer |
22 |
0 |
| t15 |
mab(s), monoclonal, antibodies, HCV, CQ, monoclonal_antibodies, HCQ, antibody, p7 |
19 |
1 |
